Business is will be picking up for plaintiff attorneys:
In a research note to clients, pharmaceutical analyst Mark Purcell of Deutsche Bank said that in the Avandia situation, “parallels will inevitably be drawn to the ongoing Vioxx litigation,” in which he said market analysts have assumed as much as $10 billion in liability for Merck.
“Assuming just half this liability for Avandia would reduce the (Glaxo) market capitalization by circa 3 percent,” Purcell wrote.
Update:
Eric Turkewitz with more.
